4//SEC Filing
Miller Andrew Craig 4
Accession 0000950170-23-013722
CIK 0001771917other
Filed
Apr 19, 8:00 PM ET
Accepted
Apr 20, 6:17 PM ET
Size
13.4 KB
Accession
0000950170-23-013722
Insider Transaction Report
Form 4
Miller Andrew Craig
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2023-04-18$9.20/sh+30,000$276,000→ 60,900 total - Exercise/Conversion
Common Stock
2023-04-20$9.20/sh+8,500$78,200→ 39,400 total - Sale
Common Stock
2023-04-18$200.16/sh−30,000$6,004,800→ 30,900 total - Sale
Common Stock
2023-04-20$200.13/sh−15,000$3,001,950→ 24,400 total - Exercise/Conversion
Option (right to buy)
2023-04-20−8,500→ 231,992 totalExercise: $9.20Exp: 2029-03-20→ Common Stock (8,500 underlying) - Exercise/Conversion
Option (right to buy)
2023-04-18−30,000→ 240,492 totalExercise: $9.20Exp: 2029-03-20→ Common Stock (30,000 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.04 to $200.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]This option vested and became exercisable in thirty equal monthly installments beginning on April 21, 2019.
Documents
Issuer
Karuna Therapeutics, Inc.
CIK 0001771917
Entity typeother
Related Parties
1- filerCIK 0001777760
Filing Metadata
- Form type
- 4
- Filed
- Apr 19, 8:00 PM ET
- Accepted
- Apr 20, 6:17 PM ET
- Size
- 13.4 KB